Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome-Reference-Cited by-同舟云学术

Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome

Published:2016-09-19 Issue:4 Volume:35 Page:734-740
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Avivi Irit¹,Cohen Yael C.¹^ORCID,Joffe Erel¹,Benyamini Noam²,Held-Kuznetsov Viki²,Trestman Svetlana¹,Terpos Evangelos³,Dimopoulos Meletios A.³,Kastritis Efstathios³

Affiliation:

1. Department of Hematology; Tel Aviv Sourasky Medical Center and Tel Aviv University; Tel Aviv Israel

2. Department of Hematology; Rambam Medical Center; Technion, Haifa Israel

3. Department of Clinical Therapeutics; National and Kapodistrian University of Athens School of Medicine; Athens Greece

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference14 articles.

1. Clonal competition with alternating dominance in multiple myeloma;Keats;Blood.,2012

2. The genetic architecture of multiple myeloma;Morgan;Nat Rev Cancer.,2012

3. Serum free light chain evaluation as a marker for the impact of intra-clonal heterogeneity on the progression and treatment resistance in multiple myeloma;Brioli;Blood.,2014

4. “Light-chain escape-multiple myeloma”-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring;Kühnemund;J Cancer Res Clin Oncol.,2009

5. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma;Larsen;Leukemia.,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Renal Outcomes in Multiple Myeloma with Involved Free Light Chains Exceeding 1000 mg/L at Diagnosis: Insights from an Indian Cohort;Indian Journal of Hematology and Blood Transfusion;2024-09-05

2. The presence of two light chain bands on immunofixation is associated with poor outcomes in newly diagnosed multiple myeloma patients;Annals of Hematology;2023-04-15

3. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV);Journal of Cancer Research and Clinical Oncology;2021-01-12

4. Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas;Laboratory Medicine;2020-11-12

5. Advanced imaging in evaluation of bone disease of multiple myeloma;Chinese Journal of Academic Radiology;2020-05-27